About Us

DM Intelligence

DM Intelligence is an artificial intelligence development company that built AI solutions for small molecule drugs with high specific and affinity. Our proprietary platform, Artificial Intelligence Drug Discovery Platform (AI-DDP), integrates artificial intelligence technologies into the medical field to provide better service to pharmaceutical companies, academic centers and biotech companies.

AI-DDP allow us to optimize leads with specific desired properties as well as design small molecules targeting specific site or receptor. Our platform has extensive capabilities of analyzing and predicting physicochemical properties, biological and toxicological activities of candidate drugs based on their structures. With all these techniques, we strive for break thoughts in the future of drug discovery and research.

Cooperation

Products


Hit Identification

Discovering a new drug is more challenge and difficult. Hit identification is the first step for a successful drug discovery project. Manual screening and high-throughput screening become cumbersome and expensive, which identify one or few compounds from hundreds, thousands or even millions of compounds with the ability to inhibit the activity of targets. We develop innovative solutions to this problem: using molecular geometry model and energy model based on structural information to predict molecule-protein interactions and identify right, validated and high-quality hits.





Predictive Models

The quality of the candidate is the key determinant of a successful outcome of drug discovery programmes. Carrying out prediction studies prior to clinical development, such as analyzing and predicting physicochemical properties, biological and toxicological activities of candidate drugs may help in reducing workload, saving time, improving efficiency.




Founder/CEO WeiDong Xie

PhD. Imperial College London.

Professor, Sun Yat-sen University

Director, St. Jude Children's Research Hospital

CTO, CK Life Science Group

CEO Lindan Biotech, Canada.

VP Biotherapy Inc
Dr. RiQiang Deng

Professor, Sun Yat-sen University

Bioinformatics scientist IT, and AI, deep learning, neural network.
Dr. Da-Wei Gu

PhD. Imperial College London

Professor in Engineering, University of Leicester

Research interests include robust control, optimal control, optimization algorithms.

Chartered Engineer

a Fellow of IET
Dr.PingHua Sun

At present, he is the head of Department of pharmacy, School of pharmacy, Jinan University

Master of pharmaceutical chemistry, Shenyang Pharmaceutical University
Doctor of Biomedical Engineering, Jinan University
University of South Florida School of Medicine / Moffitt Cancer Institute postdoctoral

College of pharmacy,Jinan University:Assistant(2002-2004)
College of pharmacy,Jinan University:lecturer(2004-2010)
College of pharmacy,Jinan University:associate professor/Master Tutor(2010-2015)
College of pharmacy,Jinan University:professor/Doctoral supervisor(2015-Now)

Partners

client client client client client client client client

News

DM Intelligence Raises Approximately ¥10 Million CNY ($1.5M USD) in Angel Round for Advance AI + Drug Discovery

April 19, 2021
Know More


DM intelligence to attend 2021 AACR annual meeting


April 13, 2021
Know More


Win win cooperation to promote the research and development of artificial intelligence innovative drugs
DEC 19, 2020
Know More
More

Teams

WeiDong Xie

Founder/CEO

RiQiang Deng

Dr.

DaWei Gu

Dr.

PingHua Sun

Dr.

Contact Us